Infiniwell Review: When Marketing Outruns the Science
SNAC absorption technology is real — for semaglutide. For BPC-157, the evidence doesn't exist.
Company Profile
Infiniwell was founded in 2020 in Dallas, Texas. The founder and CEO is Odd Sandbekkhaug, and the company is linked to Bonasana Health Limited. BBB rating is B+ (not accredited), with a file opened in July 2025. Trustpilot shows 4.7/5 from 53 reviews — a relatively small review pool.
The company’s core differentiator is its use of SNAC (salcaprozate sodium) absorption enhancement technology in oral peptide products. This technology claim is central to Infiniwell’s positioning and pricing — and it’s where the analysis gets interesting.
The SNAC Technology: Real Science, Wrong Application
SNAC is a legitimate pharmaceutical excipient. It’s not snake oil. Novo Nordisk’s use of SNAC in Rybelsus (oral semaglutide) — FDA-approved in 2019 — represents one of the most significant advances in oral peptide delivery. The original SNAC composition-of-matter patent has expired, and SNAC has received GRAS (Generally Recognized as Safe) status for use “in combination with nutrients added to food and dietary supplements.”
So the technology is real. The question is whether it works for BPC-157.
SNAC has extensive published evidence for enhancing semaglutide absorption. For BPC-157, zero published studies demonstrate SNAC enhances oral bioavailability. Infiniwell’s core marketing claim rests on an extrapolation that no published research supports.
The Extrapolation Problem
SNAC’s effectiveness is peptide-specific. The mechanism involves creating a local pH environment in the stomach that protects the peptide from acid degradation and facilitates transcellular absorption across the gastric epithelium. Whether this mechanism works for a given peptide depends on:
- Molecular weight and size (BPC-157: 1,419 Da vs. semaglutide: 4,114 Da)
- Charge distribution at gastric pH
- Folding characteristics and structural stability
- Interaction with the SNAC-created microenvironment
- Peptide-specific enzymatic vulnerability
These properties differ between BPC-157 and semaglutide. Assuming SNAC works identically across structurally different peptides has no published scientific support. It’s an assumption, not a finding.
Even if SNAC provides some absorption enhancement for BPC-157, the degree matters enormously. Rybelsus with SNAC achieves 0.4–1% oral bioavailability for semaglutide — after years of pharmaceutical optimization of the formulation. If BPC-157 + SNAC achieves similar results, a 500mcg capsule would deliver approximately 2–5mcg systemically.
The “Landmark Human Study”
Infiniwell’s marketing references a partnership with OvationLab that reportedly produced a “landmark human study” on their SNAC-enhanced BPC-157 formulation.
We searched PubMed, Google Scholar, ClinicalTrials.gov, and major preprint servers. This study does not appear in any peer-reviewed journal or registered clinical trial database. If the study exists, it has not been submitted to peer review — which means no independent scientists have verified the methodology, data, or conclusions.
A study that exists only in marketing materials is not scientific evidence. It’s a marketing claim.
Products and Pricing
| Product | Format | Price | Key Claims |
|---|---|---|---|
| BPC Rapid Pro | 60 capsules | ~$159.95 | SNAC-enhanced BPC-157 |
| BPC-157 variants | Various | $120–$160 | Various SNAC formulations |
| NMN products | Capsules | Varies | Anti-aging/longevity |
| Topical products | Creams | Varies | Skin health |
Pricing is at the premium end of the oral peptide market. The SNAC technology is the primary justification for the price premium over standard BPC-157 capsules.
Other Marketing Claims
“25,000+ healthcare professionals recommend InfiniWell”: This claim appears on the website. We could not independently verify this figure. The methodology for arriving at this number is not disclosed. Self-reported recommendation counts without third-party verification should be treated with skepticism.
COA accessibility: Certificates of Analysis are not publicly accessible on the website. For a company positioning itself as a premium, science-forward brand, this is a transparency gap.
Affiliate marketing: Infiniwell has a significant affiliate marketing presence. When evaluating online reviews of Infiniwell products, consumers should consider whether the reviewer has a financial relationship with the company.
What Consumers Should Know
Infiniwell is not the worst actor in the oral peptide market. The company has a physical presence, a BBB listing, and customer reviews suggesting the products are shipped as described. But the core marketing claim — that SNAC technology makes their BPC-157 meaningfully more bioavailable — is an unverified extrapolation that no published science supports.
If the SNAC claim were proven, Infiniwell’s pricing and positioning would be reasonable. A genuinely bioavailable oral peptide would be worth a premium.
Since the claim is unproven, consumers are paying a premium for a technology application that may or may not provide the promised benefit. The honest answer is: we don’t know if SNAC helps BPC-157 absorption, because nobody has published a study testing it.
Our Assessment
Overall Grade: C+
| Category | Score | Rationale |
|---|---|---|
| Transparency | 45/100 | SNAC claims outpace evidence; COAs not public; unverified healthcare professional count |
| Testing | 50/100 | Claims testing but documentation not publicly available |
| Pricing | 35/100 | Premium pricing based on unverified technology claims |
| Reputation | 65/100 | BBB B+; positive but limited Trustpilot reviews; no major complaints |
| Compliance | 50/100 | No FDA warning letters, but sells oral BPC-157 without NDIN |
The core issue: Infiniwell has built its brand around a technology extrapolation that no published research validates. Until a peer-reviewed study demonstrates SNAC enhances BPC-157 oral bioavailability in humans, the premium positioning is based on marketing, not science.
PeptideExaminer has no affiliate relationship with Infiniwell. We receive no compensation from this company. This review is based on publicly available information, independent research, and our standard vendor evaluation methodology. We reached out to Infiniwell for comment prior to publication. This review will be updated if the company provides published research supporting its SNAC/BPC-157 claims.
Last reviewed: February 20, 2026.